Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health: Addiction

symplr Workforce Management Software Tops Recent Rankings

Leave a comment


symplr Workforce Management Time & Attendance solution is also a 2023 Best in KLAS Award winner, and has received KLAS’ #1 ranking for the past two decades as the market-leading tool for providing mission-critical support to healthcare leaders dealing with staff shortages and disparate processes that take time away from high-value tasks. symplr software was cited for helping to provide clinicians with more freedom and flexibility to support better work-life balance and job satisfaction.

Health Data Management recently selected symplr for an exclusive “Beyond the Rankings” interview with BJ Schaknowski, CEO of symplr, and Adam Gale, CEO of KLAS, discussing how the pandemic and industry challenges, including workforce shortages, have organizations embracing partners that take different approaches to solving problems to yield measurable outcomes.

“Nurses have consistently hailed our hospital management software as the premier solution, enhancing both the quality of care provided by clinicians and the well-being of the patients they serve,” said Dr. Karlene Kerfoot, PhD, RN, FAAN, Chief Nursing Officer of symplr. “Nurses want to spend time practicing at the top of their license, and symplr enables that through precise oversight of operations and meticulous staff schedule allocation and management on an hour-to-hour basis, so the right level of support to caregivers and to patients is available.”

symplr has been dedicated to supporting healthcare and nursing for 30 years as demonstrated by The DAISY Foundation™ and AONL’s Beyond Gratitude sponsorships, and most recently with the Moments that Matter program recognizing nursing excellence by highlighting DAISY Award honorees in a remarkable video series.

The recognition of symplr’s commitment and excellence through these industry awards recognizes the company’s focused commitment in healthcare and is supported by thousands of healthcare providers and CIOs participating in these extensive evaluations.

To learn more, register here for a session called, “Streamlining operations and Tech: Where CIOs & Clinicians Align,” in which leaders from Atrium Health and symplr will highlight strategies deployed to successfully redirect clinical time back to patients.

About symplr

symplr is a leader in enterprise healthcare operations software and services. Trusted by leaders for more than 30 years, our solutions are found in 9 of 10 U.S. hospitals where our cloud-based solutions drive better operations for better outcomes. Our provider data management, workforce management, compliance, quality and safety, and contract and supplier management solutions improve the efficiency and efficacy of healthcare operations. This enables caregivers to quickly handle administrative tasks, so they have more time to do what they do best: provide high-quality patient care. Learn how at http://www.symplr.com.

Media Contact

Madeleine Smith, Matter Health for symplr, 2528146671, [email protected]

SOURCE symplr

Health

Ground-Breaking Study Confirms CurraNZ Proprietary Blackcurrant Extract, Enzans™, Increases Fat Burning by up to 61% Without Exercise

Leave a comment


The discovery shows how Enzans blackcurrant extract can increase fat burning up to 61% in sedentary adults. For the individuals in the study, the cumulative effects over a year would burn an additional 11 – 45 lbs of fat, without breaking a sweat. “Plus, we have seen in exercise-based studies that it is even more beneficial in women, so we can expect this to be of benefit in both genders,” Willems said.

In the study, researchers tested 16 healthy and physically active males at rest, following 14 days’ intake of 600mg of the CurraNZ supplement, which delivers 210mg of Enzans, the proprietary bio actives in the blackcurrant extract.

Findings showed intake of 210mg of Enzans led to:

  • Average fat burning increase of 21%
  • Individual response of up to 61%
  • Three out of four people exhibiting improved fat burning capacity

“This is extraordinary data. If you’re trying to increase all your healthy habits and using diet and exercise to lose weight, it can be a significant tool for those seeking fat loss, without doing anything extra,” Willems said.

However, for most people, diet and exercise regimes are often unsuccessful, so easy, cost-effective health strategies for inactive adults are of great interest for weight management strategies as well as the fight against Type 2 Diabetes, which Enzans has demonstrated in previous studies.

Described by researchers as an ‘extraordinary health finding for daily life’, three-quarters of the participants displayed fat burning improvements normally associated with one to three months of daily endurance exercise.

Professor Willems added, “I’m in favour of whole foods that contain polyphenols, but the problem is it’s hard to know how many anthocyanins that you are consuming in fresh foods and you might not consume enough. With a standardised blackcurrant extract, you are receiving a known amount of bio actives that provide proven and favourable changes to energy metabolism, and these supplement studies consistently show exactly what a high-quality extract can do.”

30 CurraNZ capsules retail for $39.99, available on Amazon.com or www.curranzusa.com

ABOUT CurraNZ:

CurraNZ® is a naturally sourced sports and health superfood supplement made from New Zealand blackcurrants. Each 300mg capsule delivers 105 mg of Enzans™, a proprietary, standardised dose of the bioactive anthocyanins and polyphenols found only in CurraNZ. New Zealand’s strong sunlight, high UV levels and cold winters are unique environmental factors that create a berry with one of the highest anthocyanin levels in the world and 1.5 times the concentrations found in European-grown varieties. They have been shown in over 50 published clinical studies to provide a wide range of fast-acting health benefits, including enhanced blood sugar and insulin responses, cardiovascular health, and blood flow.

Reference

Two weeks daily intake of anthocyanin-rich New Zealand blackcurrant extract enhances whole-body resting fat oxidation during supine rest in healthy males,

Dietary Supplement and Nutraceuticals 2(8), 30-40, 2023. DOI: https://www.doi.org/10.31989/dsn.v2i8.1124

Media Contact:
Margie Adelman
Adelman Public Relations
[email protected]
Mobile: 916-220-3500

SOURCE CurraNZ

health and fitness

Codoxo Shares Payment Integrity AI Outcomes at 2023 NHCAA Annual Training Conference

Leave a comment


“Codoxo provides innovative AI solutions to its healthcare payer, government agency, and PBM clients that address the growing problem of fraud, waste and abuse, which contribute to skyrocketing healthcare costs,” stated Dr. Musheer Ahmed, Codoxo’s Chief Executive Officer and founder. “The NHCAA conference enables us to share best practices for using AI-based fraud detection platforms, and we hope this will inspire attendees to integrate the latest innovations into their own fraud prevention programs.”

Codoxo will showcase its Unified Cost Containment Platform and new generative AI capabilities for payment integrity in Booth 300. The company also will host an executive networking event aboard The Spirit of Dallas on Monday, November 6, and a second networking event at The Henry on Tuesday, November 7.

Additionally, Codoxo will participate in the Symposium for Artificial Intelligence in Payment Integrity live event hosted by the AI for PI Community on Monday, November 6, prior to the start of the NHCAA conference. The AI for PI community is an exclusive community of like-minded healthcare payment integrity professionals interested in the application and value of artificial intelligence. Attendees will see how AI is transforming outcomes across the payment spectrum, learn how payers are approaching their AI strategies, and hear how health plans can apply AI to their PI operations and create a roadmap to adopting AI that will create exponential savings and improved outcomes immediately, and over time. Those interested can register here.

Codoxo is a member of NHCAA and has a stated mission “to make healthcare more affordable and effective for everyone.” Through its proprietary Forensic AI Engine, Unified Cost Containment Platform, and new generative AI capabilities, it is disrupting the cost containment and payment integrity industry by implementing the most innovative and effective AI available to reduce fraud, waste, and abuse and ensure payment integrity for health payers, agencies and PBMs.

About Codoxo
With a mission to make healthcare more affordable and effective for everyone, Codoxo is the premier provider of artificial intelligence-driven solutions and services that help healthcare companies and agencies proactively detect and reduce risks from fraud, waste, and abuse and ensure payment integrity. The Codoxo Unified Cost Containment Platform helps clients manage costs across network management, clinical care, provider coding and billing, payment integrity, and special investigation units. Our software-as-a-service applications and new generative AI capabilities are built on our proven Forensic AI Engine, which uses patented AI-based technology to identify problems and suspicious behavior far faster and earlier than traditional techniques. Codoxo is a Fierce Healthcare Innovation Award winner and has been recognized by the Inc. 5000 Regionals list for growth. Our solutions are HIPAA-compliant and operate in a HITRUST-certified environment. For additional information, visit https://www.codoxo.com.

Media Contact

Ronda Duncan, Codoxo, 8472549782, [email protected], https://www.codoxo.com 

SOURCE Codoxo

Health

RevCycle Partners Now Supports MaximEyes.com EHR and Practice Management Software

Leave a comment


MaximEyes.com becomes the tenth platform that RevCycle Partners supports. As one of the leading providers of outsourced RCM services, the company has committed to serving all the major software platforms that optometry practices rely on.

RevCycle Partners’ broad platform support allows them to assist practices that are transitioning to a new software. “It can be a challenging task to change EHR platforms,” says Colleen Lorenzo, Office Manager of True Focus Eye Care. “RevCycle Partners facilitated our conversion to MaximEyes.com with ease. We are so glad we chose RevCycle Partners for our billing needs during this transition and future growth!”

RevCycle Partners provides outsourced RCM services to eyecare practices. Outsourcing is a strategic and often cost-effective alternative to hiring staff for billing, credentialing, and eligibility and benefits verification. With its billing, credentialing, and eligibility services, RevCycle Partners’ U.S.-based team serves hundreds of practices across the United States on all the major software platforms. RevCycle Partners was cofounded by Hartge and Christine Schneider, Executive VP of Services in 2018.

Media Contact

Kirsten Tangeros, CZ Strategy, 1 847-454-5783, [email protected], czstrategy.com

SOURCE RevCycle Partners

Health

Seegene renforce son engagement en faveur d'une gestion ESG rigoureuse avec des boîtes d'expédition 100 % recyclables et exemptes de polystyrène

Leave a comment



Emballage 100 % recyclable fabriqué avec des matériaux écologiques et certifiés FSC pour répondre de manière proactive à l’évolution des réglementations environnementales mondiales La conception brevetée permet d’augmenter la capacité de charge de 30 % et de réduire les coûts de transport…

Health

Slone Partners Places Jeremy Bender, Teresa Bitetti, and David Meek as Members of the Board of Directors at Fusion Pharmaceuticals

Leave a comment


Ms. Bitetti currently serves as President of the Global Oncology Business Unit of Takeda. Previously, she held various roles of increasing responsibility at Bristol-Myers Squibb Company (BMS), including as Senior Vice President, Head of Worldwide Oncology Commercialization. At BMS, Ms. Bitetti also served as Senior Vice President and Head of the U.S. Oncology business, President and General Manager of BMS Canada, and Worldwide Head of the BMS Virology business. She currently serves on the board of Osmol Therapeutics as an independent director.

Mr. Meek most recently served as CEO and Member of the Board of Directors of Mirati Therapeutics. Prior to this role, he served as the President, CEO, and Board Member of FerGene, and CEO and Board Member of Ipsen. Mr. Meek was previously an Executive Vice President and President of Oncology at Baxalta Incorporated in the leadup to the acquisition by Shire, and Chief Commercial Officer of Endocyte. He previously held executive leadership roles at Novartis Pharmaceuticals Corporation and Novartis Oncology. Mr. Meek previously served on the Board of Directors of Entasis Therapeutics (acquired by Innoviva) and currently serves on the Board of Directors of uniQure N.V.

“Jeremy Bender, Teresa Bitetti, and David Meek are all very accomplished and highly respected leaders in the fields of biopharmaceuticals, oncology, and therapeutics,” said Leslie Loveless, Slone Partners CEO. “They bring extraordinary business and scientific experience and knowledge to the Board at a very exciting time in the company’s history.”

“We are excited to welcome Jeremy, Teresa, and David to Fusion’s Board of Directors, each bringing an exceptional breadth of experience and track record of success in oncology drug development, business development, and commercialization. Their experiences introducing innovative therapies to cancer patients as leaders of top-tier oncology companies will be invaluable as we advance our pipeline, particularly our lead program FPI-2265, which is on track to be the first actinium-based PSMA targeted alpha therapy (TAT) to market,” said Fusion Chief Executive Officer John Valliant, Ph.D. “Fusion is undergoing an exciting evolution to a later stage radiopharmaceutical company and with these appointments we are transforming our Board to maximize the value generation of our strategy.”

Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management. Ms. Bitetti holds a B.A. from Wellesley College and an M.B.A. from the Darden School of Business at the University of Virginia. Mr. Meek holds a B.A. from the University of Cincinnati.

ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

ABOUT FUSION PHARMACEUTICALS
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and AstraZeneca’s DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion’s growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical. For more information, visit the website: https://fusionpharma.com/.

Media Contact

Doug Gavel, Doug Gavel Communications, (617) 429-4417, [email protected], http://douggavel.com

SOURCE Slone Partners